830 TCR

N/A

Report date: 2025/04/10 16:18:59

Base Information

Drug Name830 TCR
Drug Alias Name830 TCR
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog modulators
TargetsGTPase KRas
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesT-Cure Bioscience Inc
China Registration ClassN/A

Develop Information

Active CompaniesT-Cure Bioscience Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A